http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3927338-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_139352097e5b57e565e2159ec902a2f5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4045 |
| filingDate | 2020-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb0b91176693434c7c9ddfe19323d35e |
| publicationDate | 2021-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3927338-A1 |
| titleOfInvention | Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders |
| abstract | Provided are compositions comprising 5-Methoxy-N,N- dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in treating major depressive disorder, wherein the 5-MeO-DMT is administered via the intravenous, intramuscular or subcutaneous route. Further provided are dosing regimens for treating this disorder. |
| priorityDate | 2019-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 84.